-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-272-genitourinary-syndrome-executive-summary.pdf
July 01, 2024 - substantial literature base, especially for vaginal estrogen
therapies that are not FDA-approved for any indication
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/breast-cancer-medications_executive.pdf
September 01, 2009 - Food and Drug Administration for
this indication and tibolone is not.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/lysosomal-storage-diseases-therapies_disposition-comments.pdf
January 01, 2014 - We recommend this sentence be revised to include
FDA‐approved indication in this statement: “One SRT … We note that some of this information about the
FDA‐approved indication appears in next paragraph, but … Lumizyme is considered by the FDA to be a
distinct product and has a different FDA-approved indication … We do note,
however, that the indication for Myozyme is correctly listed
under the column “Clinical … Indication and Outcomes
Measured in the FDA-Approved Prescribing Information.
3.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/mental-health-mobile-apps-disposition-of-comments.pdf
May 20, 2022 - tablet – thus appearing externally to be the same – each product
type has a very different purpose, indication … helps ensure that the DTx therapy is being used by the
right patient at the right time for the right indication
-
effectivehealthcare.ahrq.gov/sites/default/files/devdelays_adhd_autism_hi_impact.pdf
January 01, 2012 - Thus, no fMRI system has a labeled indication for screening or
6
AHRQ Healthcare
Horizon … It is unlikely that a manufacturer would seek a
specific labeled indication for this use. … therapy for autism
is not reimbursed because it is considered experimental or investigational for this indication
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/fetal-surgery_disposition-comments.pdf
July 05, 2011 - This minimally-invasive
approach has essentially removed the indication for
open fetal surgery for … The majority of CPAMs
however do not have an indication for
prenatal treatment as the outcomes are … circulation”
Peer Reviewer
#10
Results hydrops (not impairment of fetal lung growth) is the
indication … This minimally-invasive
approach has essentially removed the indication for
open fetal surgery for
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/colorectal-cancer-staging_disposition-comments.pdf
November 20, 2014 - and chose the
previous 5 years to manage the scope since
we were looking at studies regardless of
indication … Therefore, we limit our comments to those topics that are related to
this type of imaging and this indication … For
each indication, the guidelines rank specific value and
appropriateness. … Dose notifications are designed
to provide a clear indication to health care providers when the
parameters
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/dietary-protein-intake-executive-summary.pdf
November 01, 2024 - Executive summary_Evaluation of Dietary Protein and Amino Acid Requirements: A Systematic Review
Systematic Review
Evaluation of Dietary Protein and Amino
Acid Requirements: A Systematic Review
Executive Summary
Main Points
Background and Purpose
Protein is essential for the growth, developm…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/angina-heart-attack-treatments_executive.pdf
January 01, 2014 - ▪ Lansoprazole
▪ Rabeprazole
▪ Esomeprazole
• For patients with indication … include triple therapy (aspirin plus
antiplatelet plus anticoagulant) for UA/NSTEMI patients
with an indication … In patients with an indication for long-term
anticoagulant therapy, what are the comparative
effectiveness … without the addition of a PPI, and
(5) DAPT versus triple antiplatelet therapy in patients
with an indication … Finally,
our analysis of observational studies of DAPT and
triple therapy in patients with a long-term indication
-
effectivehealthcare.ahrq.gov/sites/default/files/medical-test-reviews-genetic.ppt
June 01, 2012 - PowerPoint Presentation
Challenges in and Principles for Conducting Systematic Reviews of Genetic Tests Used as
Predictive Indicators
Prepared for:
The Agency for Healthcare Research and Quality (AHRQ)
Training Modules for Medical Test Reviews Methods Guide
www.ahrq.gov
Challenges in and Principles for Conducting…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/medical-test-reviews-genetic.ppt
June 01, 2012 - PowerPoint Presentation
Challenges in and Principles for Conducting Systematic Reviews of Genetic Tests Used as
Predictive Indicators
Prepared for:
The Agency for Healthcare Research and Quality (AHRQ)
Training Modules for Medical Test Reviews Methods Guide
www.ahrq.gov
Challenges in and Principles for Conducting…
-
effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1406.pdf
September 26, 2014 - The indication is “for use by people with diabetes ages 16 and older, requiring insulin
as well as … Many
third-party payers cover the system according to its labeled indication for patients who meet … The
indication is “for use by people with diabetes ages 16 and older, requiring insulin as well as … payers typically provide coverage
when certain eligibility criteria are met, including the labeled indication … additional clinical trials to
demonstrate that the product is safe and effective for the proposed indication
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/atypical-antipsychotics-off-label-update_research-protocol.pdf
May 19, 2010 - our protocol (for
instance, one person suggested including insomnia, which is already an included indication
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/osteoarthritis-pain_research-protocol.pdf
August 05, 2010 - Evidence Report on the
Source: www.effectivehealthcare.ahrq.gov
Published Online: August 05, 2010
Evidence-based Practice Center Systematic Review Protocol
Project Title: Comparative Effectiveness and Safety of
Analgesics for Osteoarthritis – An Update to the 2006 Report
I. Background and Objectives f…
-
effectivehealthcare.ahrq.gov/sites/default/files/antipsychotics-children-update-disposition-170621.pdf
March 16, 2017 - because adverse events associated with an
antipsychotic are likely to be consistent
regardless of the indication … Reviewer 3 Methods I think greater justification is need for the statement
(ES-4) that confounding by indication … data plots (e.g., Figures 82-85)
indicated high variability within both types of
study design and no indication
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/antipsychotics-children-update-disposition-170621.pdf
March 16, 2017 - because adverse events associated with an
antipsychotic are likely to be consistent
regardless of the indication … Reviewer 3 Methods I think greater justification is need for the statement
(ES-4) that confounding by indication … data plots (e.g., Figures 82-85)
indicated high variability within both types of
study design and no indication
-
effectivehealthcare.ahrq.gov/sites/default/files/13_pulmonary_potential_high_impact_june_2012.pdf
January 01, 2012 - mutation occurs in about 70% of patients with CF, giving
ivacaftor the potential for a much broader indication … mutation, occurring in about 70% of patients with CF.
7
Thus, ivacaftor may gain a broader patient indication
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/copd-anticholinergic-medicines_research.pdf
December 01, 2009 - balance groups on baseline characteristics in
an effort to reduce concerns related to confounding by indication … Because of concerns about confounding by indication, we felt it was important to find a
comparable group
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/updating-criteria-qdr-protocol-amendment.pdf
December 28, 2023 - Updating the Measurement Criteria for AHRQ’s National Healthcare Quality and Disparities Report (NHQDR)
Version 5 4/18/2019 1
Evidence-based Practice Center
Technical Brief Protocol
Project Title: Updating the Measurement Criteria for AHRQ’s
National Healthcare Quality and Disparities Report (NHQDR)
Init…
-
effectivehealthcare.ahrq.gov/sites/default/files/s81.pdf
October 01, 2007 - ORIGINAL ARTICLE
Developing Indicators of Inpatient Adverse Drug Events
Through Nonlinear Analysis Using Administrative Data
Jonathan R. Nebeker, MS, MD,*†‡§ Paul R. Yarnold, PhD,¶ Robert C. Soltysik, MS,�
Brian C. Sauer, PhD,†‡ Shannon A. Sims, MD, MS,** Matthew H. Samore, MD,†‡§**
Randall W. Rupper, MD, MPH,*†‡ Ka…